Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Richard L Lindstrom
AddedFeb 13, 2024
UpdatedMay 31, 2026
Richard L Lindstrom

Richard L Lindstrom

Board Member, Ocular Therapeutix

Crunchbase

Richard L Lindstrom's Career

Ocular Therapeutix
Ocular Therapeutix

Bedford, MA, US

Board Member· Board
AcuFocus
AcuFocus

Irvine, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Richard L Lindstrom's Career

Ocular Therapeutix
Ocular Therapeutix
Public$386.5M2742006Bedford, MA, US
Board Member· Board

Leadership at Ocular Therapeutix

Antony MattessichAntony MattessichBoard Member
Merilee RainesMerilee RainesBoard Member
Amarpreet SawhneyAmarpreet SawhneyCo-Founder
Fred KhosraviFred KhosraviCo-Founder
Leslie J WilliamsLeslie J WilliamsBoard Member
Charles WardenCharles WardenBoard Member

Similar to Ocular Therapeutix

Ocular ScienceOcular ScienceManhattan Beach, CA, USEye Care ProductsOcular ScienceManhattan Beach, CA, US

Ocular Science®: A leading biotech firm innovating affordable eye care solutions.

Seed · $175.1k46
Hyperion DeFiHyperion DeFiNew York City, NY, USTherapeuticsest. 2014Hyperion DeFiNew York City, NY, US · est. 2014

Eyenovia, Inc.: A NASDAQ-listed biopharmaceutical firm innovating advanced ophthalmic therapeutics.

Public · $75.1M41
OcuCure TherapeuticsOcuCure TherapeuticsRoanoke, VA, USEye Drops, Pharmaceuticalsest. 2005OcuCure TherapeuticsRoanoke, VA, US · est. 2005

OcuCure Therapeutics: Developing innovative eye drops for age-related and diabetic eye diseases since 2005.

Public · $3.3M8
EyeCyteEyeCyteLos Angeles, CA, USTherapeuticsest. 2005EyeCyteLos Angeles, CA, US · est. 2005

EyeCyte: Developing novel therapeutics for neovascular and degenerative retinal diseases.

Series A · $3M5
AcuFocus
AcuFocus
Acquired$241.6M02001Irvine, CA, US
Board Member· Board

Leadership at AcuFocus

Charles LarsenCharles LarsenFounder
Greg MaddenGreg MaddenBoard Member
Conrad WangConrad WangBoard Member
William LinkWilliam LinkBoard Member
Arjun AroraArjun AroraBoard Member
Robert GrantRobert GrantBoard Member

Richard L Lindstrom's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Richard L Lindstrom

Brian SnowBrian SnowBoard Member · EdenFlorent CrivelloFlorent CrivelloFounder · LindyDouglas LindDouglas LindBoard Member · HyperMed ImagingHank HabichtHank HabichtBoard Member · Water Health InternationalDan L. BatrackDan L. BatrackBoard Member · Tetra TechAndy BrombergAndy BrombergCo-Founder · Sidewire